Reuters logo
BRIEF-Bayer may terminate Loxo agreement if Larotrectinib is unapproved
November 14, 2017 / 1:00 PM / a month ago

BRIEF-Bayer may terminate Loxo agreement if Larotrectinib is unapproved

Nov 14 (Reuters) - Loxo Oncology

* Agreement with Bayer includes standstill provision preventing Bayer from acquiring 5 percent or more of co’s voting securities​

* Loxo says Bayer may terminate agreement if co gets CRL from U.S. Food and Drug agency with respect to Larotrectinib - SEC filing​

* Bayer may terminate agreement if co does not get marketing approval for Larotrectinib by December 31, 2018​ Source text for Eikon: (bit.ly/2AEVqxW) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below